Massimo Guidoboni
University of Ferrara(IT)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,338 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,642 cited
- → Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma(2022)557 cited
- → Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas(2004)553 cited
- → High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability(1999)475 cited
- → Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab(2016)390 cited
- → Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma(2024)378 cited
- → Microsatellite Instability and High Content of Activated Cytotoxic Lymphocytes Identify Colon Cancer Patients with a Favorable Prognosis(2001)324 cited
- → Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma(2017)293 cited
- → Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases(2009)275 cited